Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Can you use a JAK inhibitor and Mavenclad in a patient with both multiple sclerosis and rheumatoid arthritis?
Related Questions
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
For patients on anti-CD20 therapy for MS without frequent/opportunistic infections, are there serum IgG levels or ALC levels in which you pause or change therapy due to low levels?
How would you manage a patient with LGI-1 encephalitis with faciobracial dystonic seizures who has not improved with 3 days of intravenous steroids?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
What is your disease modifying treatment of choice for a patient with relapsing remitting multiple sclerosis with treated, well controlled HIV?
How can we minimize the risk of overinterpreting reactive findings from repeat lumbar punctures?
How do you approach the "wearing off" phenomenon for patients with multiple sclerosis on B-cell-depleting therapies?
What are your vaccine recommendations while patients are on biologics?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
